Results from the first human trials of a dual broadly neutralizing antibodies regimen appeared effective, safe, and well tolerated.
With several new regimens nearing late-stage trials, a new generation of HIV antiretrovirals may soon be entering the marketplace.
Steven Deeks, M.D., and colleagues seek to define the frequency of "post-treatment controllers," who maintain control of HIV growth after discontinuing antiretroviral therapy.
Three new trials of HIV prevention drugs seek to answer directly a question that researchers inside and outside the field of HIV have explicitly avoided for years: How do drugs work -- and are they safe -- in pregnant and breastfeeding women?
An early phase clinical trial testing infusions of combination antibodies in people living with HIV has begun to evaluate whether periodic infusions of two highly potent, HIV-specific, broadly neutralizing antibodies are safe in people living with HI...
In the aftermath of the 22nd International AIDS Conference (AIDS 2018), there has been some reflecting on the challenges facing the HIV cure research field.
Invesitgators sought to determine whether human liver macrophages can sequester infectious HIV in people on antiretroviral therapy.
Researchers have demonstrated that HIV latency can be maintained in actively growing cells, a finding that may open new avenues to abolishing latency.
After 96 weeks, more people achieved viral suppression on a doravirine-based antiretroviral drug regimen compared with a darunavir (Prezista)-based one, according to data presented at the recent 22nd International AIDS Conference.
A newly published study suggests that women may respond differently than men to some HIV curative interventions that are currently under investigation or, perhaps, that an effective HIV cure for women could differ from a cure for men.